COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04588792

John Muscedere

Not reported

2020-10-19

Terminated

RCT

Randomized

Parallel

Blind label

multi-center

Treatment

inclusion criteria: subjects with respiratory failure secondary to covid-19 (sars-cov-2) infection/pneumonia requiring invasive mechanical ventilation duration of mechanical ventilation less than 48 hours as measured from the time of randomization if female, must not be pregnant at the time of enrollment as determined by a serum or urine pregnancy test

known history of severe chronic pulmonary disease (e.g., preinfection requirement for home oxygen therapy or presence of chronic hypercapnia (paco2< 50 mm hg); mild -moderate disease is still eligible in the absence of chronic hypercapnia or need for chronic oxygen therapy) in the opinion of the pi, unlikely to survive for >48 hours from time of enrollment enrollment in another trial of anti-inflammatory therapies for covid-19. known allergy to furosemide or sulfonamide agents

2

Dr. John Muscedere

18

100

Canada

Critical disease at enrollment

8: Critical disease at enrollment

40

Requirement for mechanical ventilation;Improvement in pulmonary gas exchange

None

Phase 2/Phase 3

[{"arm_notes": "", "treatment_id": 529, "treatment_name": "Furosemide", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]